FDA says Pfizer’s new RSV vaccine for older adults may trigger painful and potentially deadly Guillain-Barre syndrome in one in 10,000 patients
‘Pfizer’s new RSV vaccine for older adults may trigger the potentially deadly Guillain-Barre syndrome, the Food and Drug Administration (FDA) has warned.
In clinical trials, two participants in their 60s developed the condition that can also cause crippling pain, muscle weakness and paralysis.
One of the patients recovered after three months, but the second took six months to return to normal. They were among 20,000 adults who got the experimental shot.’
Views: